Analysts forecast that Champions Oncology Inc (NASDAQ:CSBR) will announce earnings per share (EPS) of ($0.02) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Champions Oncology’s earnings. Champions Oncology posted earnings of $0.03 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 166.7%. The business is expected to report its next quarterly earnings results on Monday, December 16th.

On average, analysts expect that Champions Oncology will report full-year earnings of $0.01 per share for the current year. For the next financial year, analysts expect that the business will report earnings of $0.20 per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Champions Oncology.

Champions Oncology (NASDAQ:CSBR) last posted its quarterly earnings data on Monday, September 16th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.09). Champions Oncology had a negative net margin of 3.61% and a negative return on equity of 48.07%. The firm had revenue of $6.74 million during the quarter, compared to analysts’ expectations of $7.50 million.

A number of analysts recently commented on CSBR shares. Zacks Investment Research raised Champions Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, September 24th. Benchmark assumed coverage on Champions Oncology in a research report on Wednesday, November 27th. They issued a “buy” rating and a $11.00 price objective on the stock. Roth Capital initiated coverage on Champions Oncology in a research note on Friday, September 20th. They issued a “buy” rating and a $9.25 price objective for the company. Finally, ValuEngine raised Champions Oncology from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $12.42.

Hedge funds have recently made changes to their positions in the business. Marshall Wace LLP purchased a new position in Champions Oncology in the first quarter valued at about $99,000. Susquehanna International Group LLP increased its stake in shares of Champions Oncology by 51.0% during the 2nd quarter. Susquehanna International Group LLP now owns 24,510 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 8,279 shares during the last quarter. Wedge Capital Management L L P NC purchased a new stake in shares of Champions Oncology during the 2nd quarter worth approximately $277,000. Alambic Investment Management L.P. raised its holdings in shares of Champions Oncology by 27.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 14,614 shares during the period. Finally, Tocqueville Asset Management L.P. raised its holdings in shares of Champions Oncology by 69.1% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 134,568 shares of the biotechnology company’s stock worth $760,000 after purchasing an additional 55,000 shares during the period. 49.33% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ CSBR traded up $0.59 during midday trading on Thursday, reaching $6.59. The company’s stock had a trading volume of 1,599 shares, compared to its average volume of 31,207. The stock has a market capitalization of $66.93 million, a P/E ratio of 662.00 and a beta of 1.20. The company has a debt-to-equity ratio of 2.06, a current ratio of 0.80 and a quick ratio of 0.80. The firm has a 50 day moving average price of $5.61 and a 200-day moving average price of $6.78. Champions Oncology has a 12-month low of $4.98 and a 12-month high of $13.21.

Champions Oncology Company Profile

Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

See Also: What is the Rule of 72?

Get a free copy of the Zacks research report on Champions Oncology (CSBR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.